Browse studies

Find your next paid study

3,839 recruiting studies matching your filters

Phase II Trial of a Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance

Background: Prostate cancer is the second most common cause of cancer-related death among men in the United States. Early-stage, low-grade prostate cancer is …

AdenocarcinomaProstate CancerNeoplasms+3 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07574541

Phase 1

A Phase 1b/2, Multicenter, Open-label, Dose Regimen Determination and Dose Expansion Trial to Evaluate the Safety, Tolerability, Anti-tumor Activity, and an Optimal Dose Regimen of Patritumab Deruxtecan (HER3-DXd) With Trastuzumab Deruxtecan (T-DXd) in Participants With Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer (HERTHENA-Breast02)

The primary purpose of the study is to assess the safety, tolerability, and anti-tumor activity of HER3-DXd and T-DXd in the combination dosing regimens in par…

Hormone Receptor PositiveHER2-low or HER2-ultralowUnresectable or Metastatic Breast Cancer

Estimated

~$10 – $7,500

Daiichi SankyoNCT07701941

Phase 3

Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) with or without nivolumab to t…

Advanced Esophageal AdenocarcinomaAdvanced Gastric AdenocarcinomaAdvanced Gastroesophageal Junction Adenocarcinoma+12 more

Estimated

~$10 – $6,250

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

Background: All childhood cancers are rare, but some are called very rare. Very rare cancers are diagnosed in 2 or fewer out of 1 million people each year. Re…

Very Rare TumorsVery Rare CancersOther Solid Tumors+2 more

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT07489378

Phase 2

A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDC…

Locally Advanced Non-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung Cancer (NSCLC)

Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT07680764

Phase 2

A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)

The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combinati…

Gastric CancerGastroesophageal Junction CancerBiliary Tract Cancer+1 more

Estimated

~$10 – $7,500

AstraZenecaNCT06219941

Phase 1

Individualized Response Assessment to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Primaries

Background: Cytoreductive surgery (CRS) removes tumors in the abdomen. HIPEC is hyperthermic (heated) chemotherapy that washes the inside of the abdomen. CRS …

Peritoneal MesotheliomaPeritoneal CarcinomatosisOvarian Cancer+4 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT04847063

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

Background: \- Laboratory investigators who are studying common childhood cancers are interested in developing a tissue repository to collect and store blood,…

SarcomaEndocrine TumorsNeuroblastoma+2 more

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT01109394

Phase 1

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid…

Metastatic Solid TumorRecurrent Solid TumorAdvanced Solid Tumor+11 more

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT06465069

Observational

AI-Driven Survivorship Care Plans (AI-SCP)

This project conducts exploratory work on a HIPAA-compliant, large language model (LLM)-based tool that integrates structured and unstructured oncology electro…

Cancer

Estimated

~$10 – $6,250

University of UtahNCT07700199

Observational

Distance-Based Exercise to Preserve Function and Prevent Disability

This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and a…

Localized Malignant Solid NeoplasmAnal CancerBladder (Urothelial, Transitional Cell) Cancer+16 more

Estimated

~$10 – $6,250

Alliance for Clinical Trials in OncologyNCT07059884

Phase 3

A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cispl…

Locally Advanced Cervical AdenocarcinomaLocally Advanced Cervical Adenosquamous CarcinomaLocally Advanced Cervical Squamous Cell Carcinoma+5 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07061977